JR
James Paul Rickey
Chief Financial Officer

James Paul Rickey insider trades: Braveheart Bio (BRVE) stock buys and sales

Chief Financial Officer, Braveheart Bio Last trade Aug 7, 2026 22 Form 4 filings
$0
Sold, last 12 months
0 sales
$500K
Bought, last 12 months
1 buy
9
Open-market trades
since 2019
3
Companies
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where James reports to the SEC

Open-market buys and sales

9 trades reported on SEC Form 4, newest first

DateStockTypeValue
Aug 7, 2026BRVE↑ Buy$500K
Jan 26, 2024ALPN↓ Sell$2.8M
Dec 19, 2023ALPN↓ Sell$292K
Dec 18, 2023ALPN↓ Sell$1.1M
Dec 6, 2023ALPN↓ Sell$1.1M
Nov 30, 2023ALPN↓ Sell$11K
Nov 6, 2023ALPN↓ Sell$289K
Dec 31, 2021ALPN↓ Sell$237K
May 30, 2019ALPN↑ Buy$50K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other BRVE insiders

Open-market trades in the last 12 months

About James Paul Rickey's insider trades

James Paul Rickey is Chief Financial Officer at Braveheart Bio (BRVE). Since May 30, 2019, James has reported 2 open-market purchases worth $549K and 7 sales worth $5.8M on SEC Form 4. In the last 12 months: 1 buy ($500K).

Their filings also include grants and awards (10 filings), option exercises (7 filings), shares withheld for taxes (2 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every BRVE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.